NSAIDs and cell proliferation in colorectal cancer

Pharmaceuticals

Volumn 3, Issue 7, 2010, Pages 2007-2021

  Ettarh, Raj ^a   Cullen, Anthony ^a   Calamai, Alvise ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Colon cancer; COX inhibitors; Cyclooxygenase

Indexed keywords

ACETYLSALICYLIC ACID; AXIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IBUPROFEN; INDOMETACIN; MESALAZINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; WNT PROTEIN;

ADENOMATOUS POLYP; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; COLON POLYPOSIS; COLORECTAL CANCER; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TREATMENT DURATION;

EID: 77955701751     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3072007     Document Type: Review

References (77)

1. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R.C.; Ghafoor, A.; Feuer, E.J.; Thun, M.J. Cancer statistics, 2005. CA Cancer J. Clin. 2005, 55, 10-30.
2. Raz, A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem. Pharmacol. 2002, 63, 343-347.
3. Kopp, E.; Ghosh, S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994, 265, 956-959.
4. Yin, M.J.; Yamamoto, Y.; Gaynor, R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998, 396, 77-80.
5. Stark, L.A.; Din, F.V.; Zwacka, R.M.; Dunlop, M.G. Aspirin-induced activation of the NF- kappaB signaling pathway: A novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 2001, 15, 1273-1275.
6. Loveridge, C.J.; MacDonald, A.D.; Thoms, H.C.; Dunlop, M.G.; Stark, L.A. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-κB. Oncogene 2008, 27, 2648-2655.
7. Pan, M.R.; Chang, H.C.; Hung, W.C. Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal. 2008, 20, 1134-1141.
8. Gu, Q.; Wang, J.D.; Xia, H.H.; Lin, M.C.; He, H.; Zou, B.; Tu, S.P.; Yang, Y.; Liu, X.G.; Lam, S.K.; Wong, W.M.; Chan, A.O.; Yuen, M.F.; Kung, H.F.; Wong, B.C. Activation of the caspase 8/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. Carcinogenesis 2005, 26, 541-546.
9. Jana, N.R. NSAIDs and apoptosis. Cell. Mol. Life Sci. 2008, 65, 1295-1301.
10. Vaish, V.; Tanwar, L.; Sanyal, S.N. The role of NF-κB and PPARgamma in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors. Tumour Biol. 2010, [Epub ahead of print].
11. Huang, Y.C.; Chuang, L.Y.; Hung, W.C. Mechanisms underlying nonsteroidal anti-inflammatory drug-induced p27(Kip1) expression. Mol. Pharmacol. 2002, 62, 1515-1521.
12. Bock, J.M.; Menon, S.G.; Goswami, P.C.; Sinclair, L.L.; Bedford, N.S.; Domann, F.E.; Trask, D.K. Relative non-steroidal anti-inflammatory drug (NSAID) anti-proliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. Mol. Carcinog. 2007, 46, 857-864.
13. Luciani, M.G.; Campregher, C.; Gasche, C. Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM. Carcinogenesis 2007, 28, 2207-2217.
14. Chen, X.J.; Xiao, W.; Qu, X.; Zhou, S.Y. NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein. Neoplasma 2008, 55, 200-204.
15. Botting, R.M. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J. Physiol. Pharmacol. 2006, 57 (Suppl. 5), 113-124.
16. Jones, D.A.; Carlton, D.P.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem. 1993, 268, 9049-9054.
17. Rigas, B.; Goldman, I.S.; Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993, 122, 518-523.
18. Eberhart, C.E.; Coffey, R.J.; Radhika, A.; Giardiello, F.M.; Ferrenbach, S.; DuBois, R.N. Up regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107, 1183-1188.
19. Sheng, H.; Shao, J.; Kirkland, S.C.; Isakson, P.; Coffey, R.J.; Morrow, J.; Beauchamp, R.D.; DuBois, R.N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 1997, 99, 2254-2259.
20. Fujita, T.; Matsui, M.; Takaku, K.; Uetake, H.; Ichikawa, W.; Taketo, M.M.; Sugihara, K. Size and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 1998, 58, 4823-4826.
21. Kikuchi, A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci. 2003, 94, 225-229.
22. Pinto, D.; Clevers, H. Wnt control of stem cells and differentiation in the intestinal epithelium. Exp. Cell Res. 2005, 306, 357-363.
23. Yanagawa, S.; van Leeuwen, F.; Wodarz, A.; Klingensmith, J.; Nusse, R. The dishevelled protein is modified by wingless signaling in Drosophila. Gene.Develop. 1995, 9, 1087-1097.
24. Yost, C.; Torres, M.; Miller, J.R.; Huang, E.; Kimelman, D.; Moon, R.T. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Gene.Develop. 1996, 10, 1443-1454.
25. Fagotto, F.; Gluck, U.; Gumbiner, B.M. Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of β-catenin. Curr. Biol. 1998, 8, 181-190.
26. Kishida, S.; Yamamoto, H.; Hino, S.; Ikeda, S.; Kishida, M.; Kikuchi, A. DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol. Cell. Biol. 1999, 19, 4414-4422.
27. Yamamoto, H.; Kishida, S.; Kishida, M.; Ikeda, S.; Takada, S.; Kikuchi, A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3β regulates its stability. J. Biol. Chem. 1999, 274, 10681-10684.
28. Coghlan, M.P.; Culbert, A.A.; Cross, D.A.; Corcoran, S.L.; Yates, J.W.; Pearce, N.J.; Rausch, O.L.; Murphy, G.J.; Carter, P.S.; Roxbee Cox, L.; Mills, D.; Brown, M.J.; Haigh, D.; Ward, R.W.; Smith, D.G.; Murray, K.J.; Reith, A.D.; Holder, J.C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7, 793-803.
29. He, T.C.; Sparks, A.B.; Rago, C.; Hermeking, H.; Zawel, L.; da Costa, L.T.; Morin, P.J.; Vogelstein, B.; Kinzler, K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281, 1509-1512.
30. Shtutman, M.; Zhurinsky, J.; Simcha, I.; Albanese, C.; D'Amico, M.; Pestell, R.; Ben-Ze'ev, A. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc. Nat. Acad. Sci. USA 1999, 96, 5522-5527.
31. Tetsu, O.; McCormick, F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398, 422-426.
32. Araki, Y.; Okamura, S.; Hussain, S.P.; Nagashima, M.; He, P.; Shiseki, M.; Miura, K.; Harris, C.C. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 2003, 63, 728-734.
33. Vogelstein, B.; Kinzler, K.W. Cancer genes and the pathways they control. Nature Med. 2004, 10, 789-799.
34. Oshima, M.; Oshima, H.; Kitagawa, K.; Kobayashi, M.; Itakura, C.; Taketo, M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc. Nat. Acad. Sci. USA 1995, 92, 4482-4486.
35. Levy, D.B.; Smith, K.J.; Beazer-Barclay, Y.; Hamilton, S.R.; Vogelstein, B.; Kinzler, K.W. Inactivation of both APC alleles in human and mouse tumors. Cancer Res. 1994, 54, 5953-5958.
36. Takeda, H.; Sonoshita, M.; Oshima, H.; Sugihara, K.; Chulada, P.C.; Langenbach, R.; Oshima, M.; Taketo, M.M. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res. 2003, 63, 4872-4877.
37. Swamy, M.V.; Patlolla, J.M.; Steele, V.E.; Kopelovich, L.; Reddy, B.S.; Rao, C.V. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 2006, 66, 7370-7377.
38. Shiff, S.J.; Koutsos, M.I.; Qiao, L.; Rigas, B. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis. Exp. Cell Res. 1996, 222, 179-188.
39. Shureiqi, I.; Chen, D.; Lotan, R.; Yang, P.; Newman, R.A.; Fischer, S.M.; Lippman, S.M. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000, 60, 6846-6850.
40. Kim, Y.H.; Kim, M.H.; Kim, B.J.; Kim, J.J.; Chang, D.K.; Son, H.J.; Rhee, P.L.; Rhee, J.C. Inhibition of cell proliferation and invasion in a human colon cancer cell line by 5-aminosalicylic acid. Dig. Liver Dis. 2009, 41, 328-337.
41. Hanif, R.; Pittas, A.; Feng, Y.; Koutsos, M.I.; Qiao, L.; Staiano-Coico, L.; Shiff, S.I.; Rigas, B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 1996, 52, 237-245.
42. Piazza, G.A.; Rahm, A.K.; Finn, T.S.; Fryer, B.H.; Li, H.; Stoumen, A.L.; Pamukcu, R.; Ahnen, D.J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997, 57, 2452-2459.
43. Williams, C.S.; Watson, A.J.; Sheng, H.; Helou, R.; Shao, J.; DuBois, R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res. 2000, 60, 6045-6051.
44. Han, A.; Song, Z.; Tong, C.; Hu, D.; Bi, X.; Augenlicht, L.H.; Yang, W. Sulindac suppresses β-catenin expression in human cancer cells. Eur. J. Pharmacol. 2008, 583, 26-31.
45. Guo, Q.; Wu, M.; Lian, P.; Liao, M.; Xiao, Z.; Wang, X.; Shen, S. Synergistic effect of indomethacin and NGX6 on proliferation and invasion by human colorectal cancer cells through modulation of the Wnt/β-catenin signaling pathway. Mol. Cell. Biochem. 2009, 330, 71-81.
46. Shureiqi, I.; Jiang, W.; Zuo, X.; Wu, Y.; Stimmel, J.B.; Leesnitzer, L.M.; Morris, J.S.; Fan, H.Z.; Fischer, S.M.; Lippman, S.M. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells. Proc. Nat. Acad. Sci. USA 2003, 100, 9968-9973.
47. Hollingshead, H.E.; Borland, M.G.; Billin, A.N.; Willson, T.M.; Gonzalez, F.J.; Peters, J.M. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 2008, 29, 169-176.
48. Stolfi, C.; Fina, D.; Caruso, R.; Caprioli, F.; Sarra, M.; Fantini, M.C.; Rizzo, A.; Pallone, F.; Monteleone, G. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem. Pharmacol. 2008, 75, 668-676.
49. Mahmoud, N.N.; Boolbol, S.K.; Dannenberg, A.J.; Mestre, J.R.; Bilinski, R.T.; Martucci, C.; Newmark, H.L.; Chadburn, A.; Bertagnolli, M.M. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998, 19, 87-91.
50. Rao, C.V.; Rivenson, A.; Simi, B.; Zang, E.; Kelloff, G.; Steele, V.; Reddy, B.S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 1995, 55, 1464-1472.
51. Moorghen, M.; Ince, P.; Finney, K.J.; Sunter, J.P.; Appleton, D.R.; Watson, A.J. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J. Pathol. 1988, 156, 341-347.
52. Moorghen, M.; Orde, M.; Finney, K.J.; Appleton, D.R.; Watson, A.J. Sulindac enhances cell proliferation in DMH-treated mouse colonic mucosa. Cell Prolif. 1998, 31, 59-70.
53. Narisawa, T.; Satoh, M.; Sano, M.; Takahashi, T. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 1983, 4, 1225-1227.
54. Reddy, B.S.; Rao, C.V.; Rivenson, A.; Kelloff, G. Inhibitory effect of aspirin on azoxymethane induced colon carcinogenesis in F344 rats. Carcinogenesis 1993, 14, 1493-1497.
55. Jacoby, R.F.; Marshall, D.J.; Newton, M.A.; Novakovic, K.; Tutsch, K.; Cole, C.E.; Lubet, R.A.; Kelloff, G.J.; Verma, A.; Moser, A.R.; Dove, W.F. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 1996, 56, 710-714.
56. Jacoby, R.F.; Seibert, K.; Cole, C.E.; Kelloff, G.; Lubet, R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000, 60, 5040-5044.
57. Rao, C.V.; Steele, V.E.; Swamy, M.V.; Patlolla, J.M.; Guruswamy, S.; Kopelovich, L. Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res. 2009, 69, 8175-8182.
58. Kohno, H.; Suzuki, R.; Sugie, S.; Tanaka, T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC cancer 2005, 5, 46.
59. Giardiello, F.M.; Hamilton, S.R.; Krush, A.J.; Piantadosi, S.; Hylind, L.M.; Celano, P.; Booker, S.V.; Robinson, C.R.; Offerhaus, G.J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993, 328, 1313-1316.
60. Giardiello, F.M.; Yang, V.W.; Hylind, L.M.; Krush, A.J.; Petersen, G.M.; Trimbath, J.D.; Piantadosi, S.; Garrett, E.; Geiman, D.E.; Hubbard, W.; Offerhaus, G.J.; Hamilton, S.R. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med. 2002, 346, 1054-1059.
61. Thun, M.J.; Namboodiri, M.M.; Heath, C.W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 1991, 325, 1593-1596.
62. Giovannucci, E.; Rimm, E.B.; Stampfer, M.J.; Colditz, G.A.; Ascherio, A.; Willett, W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 1994, 121, 241-246.
63. Lanas, A.; Ferrandez, A. NSAIDs and the colon. Curr. Opin. Gastroenterol. 2009, 25, 44-49.
64. Sano, H.; Kawahito, Y.; Wilder, R.L.; Hashiramoto, A.; Mukai, S.; Asai, K.; Kimura, S.; Kato, H.; Kondo, M.; Hla, T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995, 55, 3785-3789.
65. Kargman, S.L.; O'Neill, G.P.; Vickers, P.J.; Evans, J.F.; Mancini, J.A.; Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995, 55, 2556-2559.
66. Piazza, G.A.; Keeton, A.B.; Tinsley, H.N.; Gary, B.D.; Whitt, J.D.; Mathew, B.; Thaiparambil, J.; Coward, L.; Gorman, G.; Li, Y.; Sani, B.; Hobrath, J.V.; Maxuitenko, Y.Y.; Reynolds, R.C. A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev. Res. 2009, 2, 572-580.
67. McGarvey, M.A.; O'Kelly, F.; Ettarh, R.R. Nimesulide inhibits crypt epithelial cell proliferation at 6 hours in the small intestine in CD-1 mice. Dig. Dis. Sci. 2007, 52, 2087-2094.
68. McGarvey, M.A.; Bass, G.; Ettarh, R.R. Nimesulide alters cell recruitment into mitosis in murine intestinal crypts without influencing the cell production rate. Dig. Dis. Sci. 2007, 52, 1471-1478.
69. Baron, J.A. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog. Exp. Tumor Res. 2003, 37, 1-24.
70. Mahmud, S.M.; Tanguay, S.; Begin, L.R.; Franco, E.L.; Aprikian, A.G. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur. J. Cancer Prev. 2006, 15, 158-164.
71. Murad, A.S.; Down, L.; Smith, G.D.; Donovan, J.L.; Lane, J.A.; Hamdy, F.C.; Neal, D.E.; Martin, R.M. Associations of aspirin, non-steroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: Findings from a large, population-based, case-control study (the ProtecT study). Int. J. Cancer 2010, [Epub ahead of print].
72. Jacobs, E.J.; Rodriguez, C.; Mondul, A.M.; Connell, C.J.; Henley, S.J.; Calle, E.E.; Thun, M.J. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl. Cancer Inst. 2005, 97, 975-980.
73. Platz, E.A.; Rohrmann, S.; Pearson, J.D.; Corrada, M.M.; Watson, D.J.; De Marzo, A.M.; Landis, P.K.; Metter, E.J.; Carter, H.B. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 390-396.
74. Brasky, T.M.; Bonner, M.R.; Moysich, K.B.; Ambrosone, C.B.; Nie, J.; Tao, M.H.; Edge, S.B.; Kallakury, B.V.; Marian, C.; Trevisan, M.; Shields, P.G.; Freudenheim, J.L. Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 2010, [Epub ahead of print].
75. Cronin-Fenton, D.P.; Pedersen, L.; Lash, T.L.; Friis, S.; Baron, J.A.; Sorensen, H.T. Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res. 2010, 12, R15.
76. Cuzick, J.; Otto, F.; Baron, J.A.; Brown, P.H.; Burn, J.; Greenwald, P.; Jankowski, J.; La Vecchia, C.; Meyskens, F.; Senn, H.J.; Thun, M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol. 2009, 10, 501-507.
77. Rayburn, E.R.; Ezell, S.J.; Zhang, R. Anti-inflammatory agents for cancer therapy. Mol. Cell. Pharmacol. 2009, 1, 29-43.